Navigation Links
ViroPharma to Release 2010 Fourth Quarter and Full Year Financial Results on February 24, 2011
Date:2/10/2011

EXTON, Pa., Feb. 10, 2011 /PRNewswire/ -- ViroPharma Incorporated's (Nasdaq: VPHM) fourth quarter and year end financial results for 2010 are expected to be released on Thursday, February 24, 2011 before the open of the U.S. financial markets.

The company will host a conference call and live audio webcast at 9:00 a.m. Eastern Time on the same day.  During the conference call, ViroPharma management will discuss the 2010 fourth quarter and full year financial results and other business.

The press release and the live webcast of the conference call will be accessible via ViroPharma's corporate website at http://www.viropharma.com.  An audio archive will be available at the same address until March 18, 2011.  To participate in the conference call, please dial (888) 299-4099 (domestic) and (302) 709-8337 (international).  After placing the call, please tell the operator you wish to join the ViroPharma investor conference call.  

About ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing innovative products for physician specialists to enable the support of patients with serious diseases for which there is an unmet medical need, and providing rewarding careers to employees.  ViroPharma commercializes Cinryze® (C1 esterase inhibitor [human]) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE).  ViroPharma commercializes Vancocin®, approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx).  ViroPharma currently focuses its drug development activities in diseases including C1 esterase inhibitor deficiency and C. difficile.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ViroPharma to Participate in Several Upcoming Healthcare Investor Conferences
2. ViroPharma Receives Complete Response Letter for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Supplement
3. ViroPharma to Release 2010 Third Quarter Financial Results on October 27, 2010
4. ViroPharma to Present at the Jefferies 2010 Global Healthcare Conference
5. ViroPharma Announces Presentation of Data from Non-Toxigenic Clostridium difficile (VP20621) Phase 1 Study
6. ViroPharma To Participate in Two September Healthcare Investor Conferences
7. ViroPharma Announces Publication of Cinryze™ (C1 Esterase Inhibitor [Human]) Phase 3 Trial Results in Hereditary Angioedema (HAE) in the New England Journal of Medicine
8. ViroPharma Files Prior Approval Supplement (PAS) for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Manufacturing
9. ViroPharma to Participate in Two June Healthcare Investor Conferences
10. ViroPharma To Host Investor Day
11. ViroPharma to Participate in the Cowen and Company 30th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... May 3, 2016 ... dass sie einen entscheidenden Meilenstein durch diese ... Aufruf zum Handeln, um Patientenresultate  bei Verdauungs- ... zu Fortschritten im Verständnis der Hepatischen Enzephalopathie ... Bewusstsein für Hepatische Enzephalopathie in der Öffentlichkeit ...
(Date:5/2/2016)... Mass. , May 2, 2016  While nearly ... that osteoporosis can have on their health, only about ...   according to the results of a new survey ... To mark the start of National Osteoporosis Month, Hologic ... health, which affects nearly 56 million Americans. ...
(Date:4/29/2016)... 29, 2016 ReportsnReports.com adds ... market research report that provides an overview of ... at various stages, therapeutics assessment by drug target, ... and molecule type, along with latest updates, and ... key players involved in the therapeutic development for ...
Breaking Medicine Technology:
(Date:5/3/2016)... ... May 03, 2016 , ... Horizon Blue Cross Blue ... as one of the nation’s most accomplished business technology innovators by InformationWeek, earning ... recognition for technology achievements that have enabled the delivery of the company’s innovative ...
(Date:5/3/2016)... ... , ... Elizabeth Murray has always loved walking one to two miles a ... shoulder and one on her arm. But she got to the point where she ... prolapse. , The valves of the heart wouldn’t close properly resulting in mitral regurgitation, ...
(Date:5/3/2016)... , ... May 03, 2016 , ... ... online university, has announced today the launch of its Associates and Bachelor's degrees ... President Emeritus of The Rockefeller University, Dr. Torsten N. Wiesel; Chairman and CEO ...
(Date:5/3/2016)... (PRWEB) , ... May 03, 2016 , ... Boston Children’s ... can rehearse tough medical situations or practice tricky or rare procedures in an environment ... Area, the SIM Center is also available to inventors and “hackers” to develop and ...
(Date:5/3/2016)... ... 2016 , ... Park Cities Pet Sitter has openings for both full-time and ... 75206, 75209, 75219, 75220, 75225, 75229, 75230, 75231 and 75235 zip codes. These ... Preston Hollow and Park Cities areas of the Metroplex. Candidates must love animals, ...
Breaking Medicine News(10 mins):